Results 201 to 210 of about 8,924,877 (409)

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy

open access: yesScience, 2015
A. Sivan   +11 more
semanticscholar   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

open access: yesMolecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia   +9 more
wiley   +1 more source

A guide to reactive oxygen species in tumour hypoxia: measurement and therapeutic implications

open access: yesMolecular Oncology, EarlyView.
Hypoxia reshapes tumour redox landscapes by altering compartmental ROS production (mitochondria, NOX, ER, peroxisomes). Accurate interpretation requires oxygen‐contextualised measurement (live biosensors, chemical probes, EPR, LC–MS) and awareness of artefacts (reoxygenation, probe specificity).
Lina Hacker   +3 more
wiley   +1 more source

Efficacy or effectiveness? [PDF]

open access: yesJournal of Internal Medicine, 2006
M. H. Pittler, Edzard Ernst
openaire   +3 more sources

Identifying prognostic targets in metastatic prostate cancer beyond AR

open access: yesFEBS Open Bio, EarlyView.
Genome‐wide functional screens combined with a large gene expression database and clinical outcomes can identify new therapeutic vulnerabilities in prostate cancer. Eight potentially druggable targets demonstrated strong dependency in cell lines, were associated with worse prognosis clinically, and showed evidence of protein expression in prostate ...
Emily Feng   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy